Kobe Medical Industry Development Project. Takashi MIKI Director, Planning and Coordination Bureau City of Kobe



Similar documents
5HJHQDWLYH 0HGLFLQH,QGXVWU\ LQ -DSDQ

Advanced Total Healthcare Solutions of Hitachi Group Corporations

Stem Cells and Inner Ear Cell Regeneration. Stefan Heller Stanford University School of Medicine

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine

Summary of Act for Appropriate Provision of Hematopoietic Stem Cells to be Used in Transplantations

Introduction. 1. General outline. 1) Position of the Healthcare Policy. 2) Basic principles of the Healthcare Policy (Article 2 of the Promotion Act)

RITMIR024 - STEM CELL RESEARCH IN CARDIOLOGY

Stem Cell Quick Guide: Stem Cell Basics

Regulatory Updates on Cellular Therapy Products in Japan

Experience a higher excellence.

TERUMO Corporation Business Strategy Conference

Diluted net income per share. Total assets Net assets Equity ratio Net assets per share

Introduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure

Contact Points on Government Procurement as of January 1, 2005

LifeNet Health Presented by James Clagett, PhD., Chief Science Officer LifeNet Health - The Best Keep Secret in Regenerative Medicine

Development of Advanced Medicine at Nagoya University. Center for Advanced Medicine and Clinical Research. Nagoya University Hospital

Roche Position on Human Stem Cells

Establishing a Presence in Japan. Hitoshi Oishi, Executive Director, JETRO Toronto

Toward Acceleration of Open Innovation

Hitachi Healthcare Company - Our Strategy and Opportunities -

SÁNCHEZ MARGALLO, Francisco Miguel

The National Centre for Biomedical Engineering Science

STEM CELL FELLOWSHIP

What are Stem Cells? How can they be used in medicine?

Exploratory Brief on Nanomedicine or the Application of Nanotechnology in Human Healthcare

Biobanking Pluripotent Stem Cell Lines: UK and EU regulations Glyn Stacey, UK Stem Cell Bank, NIBSC

NORTH CAROLINA STATE UNIVERSITY NORTH CAROLINA STATE UNIVERSITY Office of Technology Transfer

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com

It s not something you want to think about, but it s something you want to prepare for.

Achievement of Korea s Healthcare Industry. Devices. World s largest market share in ultrasound imaging devices ( 14) Competitiveness

STEM CELL FACTS. The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine.

Global 30 Course List

Stem Cell Research: Adult or Somatic Stem Cells

US Regulations for Import and Export of Cell Therapy Products

Policy statement. Stem cell research

A Core Clinical Research Hospital to provide world class advanced medical care

[Indian Stem Cell Banking Market: Trends & Opportunities ( )]

Intellectual Property Management of Biotechnology Start-ups and Companies in Japan

Top Ten Things to Know About Stem Cell Treatments

your complete stem cell bank

Overview of the Japanese Pharma & Healthcare Market JETRO Seminar October 2013 Anil Vaidya Life Science Consultant

CONSULTATION RESPONSE

Business Set up in Japan

JUMISC JUMISC. For further information visit our website:

Donna J. Dean, Ph.D. October 27, 2009 Brown University

FACULTY OF ALLIED HEALTH SCIENCES

Vita 34 Parents Guide to umbilical Cord Blood Banking. secure first-class innovative

Inviting Possibilities. Healthcare. Cover Page- Healthcare Sector Report.indd 1

Alexander Smolyaninov,

Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights

tem ells /background /information Stem cell research Copyright 2007 MRC Centre for Regenerative Medicine, Institute for Stem Cell Research

Australia Life Sciences Market

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research

Stem Cell Collection Preservation Research Processing East Seven Mile Detroit, MI fax

Floor Plans. 5th Floor. 4th Floor. 3rd Floor

Challenge of FUJIFILM in Medical ICT

Stem Cells: Scientific Progress and Future Research Directions

Act for Appropriate Provision of Hematopoietic Stem Cells to be Used in Transplantations

Business Challenges Over the Past 40 Years

TRAINING AND DIALOGUE PROGRAMS

For your future business development, we offer suitable business environment. Welcome to Wakayama

Kazan (Volga region) Federal University, Kazan, Russia Institute of Fundamental Medicine and Biology. Master s program.

Entrepreneurship Education at the University of Tokyo

The Industrial Translation Market in Japan

One of the most important recent developments in cancer treatment has been the ability to harvest stem

Information for patients and the public and patient information about DNA / Biobanking across Europe

STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE

Sarah A. Haecker, PhD 1782 Humboldt Avenue Minneapolis, Minnesota

The Texas Biotechnology Industry

The Types of stem cells: Totipotent Pluripotent Multipotent

Recent Developments in Governmental Regulation of Biomedicine in Japan. Eiji Maruyama Kobe University Graduate School of Law Kobe, Japan

Automating Cell Biology Annual general meeting, September 7, Phase Holographic Imaging

Hyogo Prefectural Employment Development Association The Kobe Chamber of Commerce and Industry

Graduate School of Pharmaceutical Sciences

Stem cells possess 2 main characteristics: Sources of pluripotent stem cells: -Long-term self renewal. -The inner cell mass of the blastocyst.

Paro Found to Improve Brain Function in Patients with Cognition Disorders

Brochure More information from

well foresight studies opportunities for regenerative medicine in the netherlands royal netherlands academy of arts and sciences

SciRevision Japanese Clients/pro bono: Universities, Institutes, Companies (updated 1 November, 2007)

MediSapiens Ltd. Bio-IT solutions for improving cancer patient care. Because data is not knowledge. 19th of March 2015

Risk Management Plan (RMP) Guidance (Draft)

ICT. Overview. The Information and Communications Industry Japan s Largest Industry. Contribution to real GDP by industry (2010)

Japan s Changing Medical Care Scene

Briefing on the second reading of the Human Fertilisation and Embryology Bill, Monday 19 November 2007.

Special Feature: Growth Model of an Agile Company

ACC San Diego Chapter

Guidance For Research Involving Human Embryonic Stem Cells, Germ Cells, And Cells Obtained From Cord Blood

Unit 1 Higher Human Biology Summary Notes

LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi

Version Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen

Supporting Overseas Companies Doing Business in Tokyo. Noriko Suzuki. Tokyo Metropolitan Government. Tokyo Investment and Business Seminar

Elective Options for MS in Clinical and Translational Sciences Program

Japan. Type of Market: Large/Challenging. Overall Rank ITA Health IT Top Markets Report 35

Anforderungen der Life-Science Industrie an die Hochschulen. Hans Widmer Novartis Institutes for BioMedical Research

UCF, College of Medicine BS Biotechnology MS Biotechnology/MBA Professional Science Masters Program in Biotechnology/MBA

PT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank

House Resolution No. 37

It is worth investing here :51:30

Biotech Opportunities for Start-Up Firms in Japan and Asia

Tsubame Patent Attorney Firm at a Glance. Tsubame Patent Attorney Firm Registered Patent Attorney Itsuki Shimbo PhD.

Transcription:

Kobe Medical Industry Development Project Takashi MIKI Director, Planning and Coordination Bureau City of Kobe 0

Where is KOBE? GERMANY JAPAN KOBE 6 th largest city in Japan Population: approx. 1.5 million Area: 550 km2 GDP: approx. 43 billion ( 6 trillion) KANSAI area KANSAI area Japan s Second Largest Economic Zone Population: approx. 21 million GDP: approx. 640 billion ( 89 trillion) Fukuoka JAPAN KOBE Nagoya Osaka Sapporo TOKYO Berlin Population: approx. 3.5 million Area: approx. 891 km2k 1 1

Convenient Transportation AIR Kansai International Airport (30 min. by marine transport) Kobe Airport (Opened on February 16 th 2006) OVERLAND Bullet train, Highway SEA Port of Kobe Port Island Kobe Airport Marine Air 2

Kobe Medical Industry Project Core Facilities Planned site for relocation of the Kobe City General Hospital (2010) To downtown BT Port Liner Kobe City General Hospital To Sannomiya Port Island CDB IBRI BMA TRI KIMEC Core Facilities KIBC Molecular Imaging Center and Healthcare Devices Development Center (Under construction) KIO Kobe Airport (Opened on Feb. 16 th 2006) Port Liner Marine Transport to Kansai International Airport CDB: RIKEN Center for Developmental Biology IBRI: Institute of Biomedical Research and Innovation BT: Kobe Biotechnology Research and Human Resource Development Center BMA: Business Support Center for Biomedical Research Activities TRI: Translational Research Informatics Center KIBC: Kobe International Business Center KIO: Kobe Incubation Office MEDDEC: Kobe Medical Device Development Center MEDDEC To Kobe Airport 3

History 1998.10 :Established the Kobe Medical Industry Development Project Discussion Group Chairman Dr. Hirô Imura (President of Kobe City General Hospital at that time) 1999.12 :Budgeted for IBRI and RIKEN CDB (Millennium Project) 2000. 2 :Approved as the Special Earthquake Restoration Project 2001. 8 :Approved as the 2 nd selection of the Urban Renaissance Project 2002. 4 :Approved as the Knowledge Cluster Initiative 2003. 4 :Approved as the Deregulation Zone for Advanced Medical Industry 2005. 4 :Established the Council for Life Science Promotion MEDDEC Kobe Airport Port Island Minami sta. KIBC IBRI RIKEN CDB KIMEC TRI Sentan Iryo Center Mae sta. BMA BT Center To Sannomiya Photo: March 2006 (South view) 4

Core Functions Develop as a focal point for R&D of highly advanced medical technology Establish a streamlined process from basic research to clinical application and industrialization Target fields Medical device Clinical research and trials Regenerative medicine Core functions Translational research Construction of a next generation medical system Goals Create new employments and revitalize local economy Provide high level medical services and welfares for Kobe citizens Support for business development Human Resource Development Contribution on an improvement of medical technologies in Asian countries 5

Developing Japan s s First Life Science Cluster Data complied by Bechtel/ SRI (2000) Primary factors behind the development of industrial clusters 1Preparation of core research facilities 2Structured cooperation with universities and research institutions 3Effective use of airport facilities Project aims (economic effect) - New employment created: 23,000(Kansai region) 18,000(Kobe) - Production generated: 530 billion yen(kansai region) 330 billon yen(kobe) Effective collaboration with related research institutions and universities Spring-8 Upgrade existing industries Attract related industries Access to world markets Kobe Univ. National Cardiovascular Center Port Island Kobe Medical Industry Development Project Core Facilities Kobe Airport Synergy with Kobe Airport AIST TERC Kansai International Airport Kansai regional network Kyoto Univ. Osaka Univ. Saito (International Culture Park) Project AIST: National Institute of Advanced Industrial Science and Technology Collaboration with advanced businesses and research institutions around the world 6

Institute of Biomedical Research and Innovation Administration: Foundation for Biomedical Research and Innovation Medical treatments and clinical researches being carried out: 1Hematopoietic stem cell transplants (Bone-marrow transplants, cord blood stem cell transplants) 2Peripheral blood vessels regeneration of the lower extremities and cardiovascular regeneration 3Dental implants and regeneration of alveolar bone 4Diagnosis and medical treatment using PET and CT-Linac 5Cerebrovascular therapy 6Chemotherapy for cancer 7Clinical trials on pharmaceuticals and medical devices 7

Cell Processing Center IBRI Olympus Corporation : Regenerate bone by differentiate stem cell of bone marrow into osteocyte on the β-tcp which has bio-affinity BMA Teijin Limited: Establish new therapy which is to cultivate chondrocyte in vitro, and return to damaged articular cartilage Terumo Corporation: Regenerate myocardium by cultivate skeletal myoblast of skeletal muscle ArBlast Co., Ltd. : Regenerate alveolar bone in dental surgery area by cultivate stem cell of bone marrow Hitachi Medical Corporation: Manufacture regenerative medicine materials, and establish safety Genemedicine Japan Inc.: Develop every kind of GMP graded virus vector for gene therapy Stem Cell Science KK: Produce therapeutic use cell 8

Research and Development of Medical Devices PET camera CT-Linac Ultra high magnetic field MRI 4D Linac Medical Devices Development Study Group (consists of 70 companies, most of them are members of Kobe Machinery and Metal Firms Association Inc. and 11 medical device companies) participate in. 9

Support for Clinical Trials Operation of Clinical Trial Model Project: Installation of the clinic (October 2000) Cooperative clinical trials with local hospitals and clinics: -Establish network between IBRI and local medical institutions to handle life-style-related diseases -Community Based Clinical Trial Study Meetings (2000. 12 ~ 2001. 7) - Basic Agreement (2002. 3) -Co-sponsoring community-based clinical trial seminars with Kobe Doctors Association (2002. 11~) Training for Clinical Trial Coordinator: Operation of training sessions for nonexperienced and experienced people 1200 1000 800 600 400 200 0 High Blood Pressure Group Number of Clinical Trials Phase 1 Phase 2,3 Suspension 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998year Community based clinical trials Hospitals & Clinics Allergy Group Kobe City General Hospital Hospitals & Clinics Diabetes Group Hospitals & Clinics Support/ CRC Clinical trial reviewing committee IBRI 10

RIKEN Center for Developmental Biology(CDB) RIKEN Center for Developmental Biology(CDB) ~ A world-class center in the field of embryology and stem cell research~ Research Groups Director: Dr. Masatoshi TAKEICHI Ph.D. 7 core program directors including Director Takeichi 23 creative research promotion programs Number of researchers: 243 (30 research groups) Major research fields Mechanism of Development Mechanism of Regeneration Application to Medicine ES Cell (mouse) Research Building C Research Building A Planarian (length 1cm) Animal Facility Research Building B Zebra fish (length 3 cm) 11

Translational Research Informatics Center (TRI) Other Core Facilities Ⅰ Providing information and supporting for translational research Management of clinical trial and supporting data management Establishment of management system of disease data and outcome research data Providing cancer-related information via internet Business Support Center for Biomedical Research Activities (BMA) Support bio-ventures and companies related to regenerative medicine Cell Processing Center Animal laboratory RI facility 12

Other Core Facilities Ⅱ Kobe Biotechnology Research and Human Resource Development Center (BT Center) / Kobe University Business Incubation Center State-of-the-art and cross field research and human resource development Kobe Medical Device Development Center (MEDDEC) R&D and training of catheter and endoscope Operating room MRI laboratory Device development corner for small-medium companies Rental laboratory Breeding and observation space 13

Kobe Healthcare Devices Development Center (tentative name) Building completion in September 2006 Development of Bio-experiment devices Diagnostic and preventive devices Healthcare devices Other Core Facilities Ⅲ Molecular Imaging Research and Development Center Building completion in September 2006 RIKEN, venture company Speeding up the process of identifying candidate materials for the design of new drugs and medications 14

Incentives for businesses Kobe Biomedical Venture Fund Total 6.3 billion yen invested in total 69 companies Sumitomo Mitsui Banking Corporation Group Venture capital fund specific for biomedical industries Technical assessments carried out by Technology Assessment Committee handled by FBRI Kobe Life Science IP Fund 0.5 billion yen invested in 3 companies Nomura Research & Advisories Starting up venture companies based on intellectual properties Incentives based on the Kobe Enterprise Zone Ordinance Tax reductions, Subsidies Establishment of the Pilot Enterprise Zone Land rents for 10 years without charge(port Island 2nd stage) Establishment of the Pro-Cluster Kobe Industrialization Support, Human Resource Development, Providing Information 15

MedCollabo KOBE ~ Business Network in the project ~ Establishment: November, 2004 Mission/Objectives : To enhance relationship among companies in the project To promote and accelerate the formation of KOBE Biomedical Cluster Support Organizations: Foundation for Biomedical Research and Innovation, The Kobe Chamber of Commerce and Industry KOBE Medical Industry Development Project Port Island 2nd Stage Zone BT Center (4) IBRI (7) KIBC (35) Port Island BMA (14) TRI (3) KIMEC (13) Plant Area (4) ( ); number of companies Kobe Airport PEZ (4) KIO (4) MEDDEC (9) Molecular Imaging Center (1) Total; 87 companies Coordination of Joint R&D, Alliance and Tie-up with outside academics and companies Planning Business Tour, Joint promotion, etc. Making proposals to the city of Kobe office and the central government 16

6 6 81 17 17

Profiles of 87 companies Company Size Activity in Kobe Others 26% 23 18 Giant companies 21% Ventures 53% 46 Sales 22 Manufacturing, 58 Service 25% Research, Development 67% 7 8% 18

Support System to promote International Bio-Venture Asian Bio-Cluster Medical Device Pharmaceutical Generic Bio-venture Network of Universities and Research Institutes in Kansai area Satellite Office in Kobe (PRO-CLUSTER KOBE) EU-Bio-Cluster Drug Development Diagnosis Therapeutic device Drug Delivery System Licensing Bio-venture Promotion Fund Support to obtain a patent Introduce Influential Companies Cooperation between universities and companies Create International Bio-venture in Kobe MEDDEC TRI Development Support Clinical Research Marketing Support Pharmaceutical Trading Companies CRO Venture Capital Medical Devices 19

2 Utilize seeds of companies 4 Strategy to attract more tourists and revitalize economy by establishing health-related leisure activities Healthcare program related to Kobe Medical Industry Development Project Academic Zone Athlete town project Kobe City General Hospital 3Attract and accumulate health related companies Medical institutions Kobe Medical Industry Development Project Core Facilities Counseling On going health management by medical checkup at home Health Insurance Associate Companies Sports facilities 1 Local support system to maintain citizens health Healthcare promotion for Kobe citizens Revitalize local economy Improve Kobe s fascination Tourists from inside and outside Japan Kobe Airport Kansai International Airport 20

Outline of Kobe Life Science Innovative Program 3 Propose a cluster promotion plan to invigorate local economy Kobe Gakuin University Academic Zone Hyogo College of Medicine Shukugawa Gakuin College Planned site for relocation of Kobe City General Hospital Medical Zone CDB Research Zone (Core facilities Zone) 2 Propose a new plan of research and technology development in life science field IBRI KIBC Kobe Airport Kobe City General Hospital BT Center BMA TRI KIMEC Council Member (formed in April 2005) Chairman: Hirô Imura (Chairman of FBRI) Member: : Researchers of university and research institute in Kansai area in medical, engineering and social science field Business community of Kobe Local Doctor s s Association Local small & medium sized companies Companies expanded into Port Island 2 nd stage Observer: Hyogo prefecture Ministry of Health, Labour and Welfare Ministry of Economy, Trade and Industry Ministry of Education, Culture, Sports, Science and Technology 1 Propose grand designs of after 10 and 20 years R&D Zone (Companies/ Venture Zone ) PEZ KIO MEDDEC Molecular Imaging R&D Center and Healthcare Devices Development Center 21